For those with stubbornly resistant forms of severe depression, ketamine was looking more and more like a solution. Years of research has hinted at the dissociative anesthetic’s treatment potential where other medications failed, promising the benefits of electroshock therapy with far fewer risks.

For all of the excitement, separating the hope from the hype has been challenged by the drug’s strong psychoactive effects. How can you conduct a blind test for a drug that so overtly detaches the mind from the body?

By taking advantage of the unconscious state of patients under general anesthesia, researchers from Stanford University School of Medicine in the US put ketamine to the ultimate, gold standard test.

Having more pixels could advance everything from biomedical imaging to astronomical observations.

Researchers at the National Institute of Standards and Technology (NIST) and their colleagues have built a superconducting camera containing 400,000 pixels — 400 times more than any other device of its type.

Superconducting cameras allow scientists to capture very weak light signals, whether from distant objects in space or parts of the human brain. Having more pixels could open up many new applications in science and biomedical research.

A meta-analysis showed improvement of neuropsychiatric symptoms with acetylcholinesterase inhibitors in Alzheimer disease and Parkinson disease, although effect sizes were small.

Neuropsychiatric symptoms are challenging to treat in patients with neurodegenerative conditions. In this meta-analysis, researchers investigated the effect of cholinesterase inhibitors (ChEI) on neuropsychiatric symptoms in those with Alzheimer disease (AD) or Parkinson disease (PD). Studies in the analysis included placebo-controlled, randomized clinical trials that included at least one ChEI — i.e., donepezil, rivastigmine, or galantamine — and applied at least one validated neuropsychiatric measure, with the Neuropsychiatric Inventory (NPI) being the most used measure studied. The primary outcomes were hallucinations and delusions. Secondary outcomes included all other neuropsychiatric outcomes.

Original participant data for 6,649 individuals with AD or PD from 17 trials were available for analysis out of 34 eligible trials. In patients with AD, ChEI use was associated with significantly fewer delusions (effect size, −0.08) and hallucinations (−0.09) compared with placebo. In the PD subgroup, ChEIs also were associated with significantly fewer delusions (−0.14) and hallucinations (−0.08). These effects did not differ among ChEI types. ChEIs were associated with lower appetite scores in the AD group and with significantly improved total neuropsychiatric scores in the PD group (−0.18). Increases in baseline neuropsychiatric scores were associated with greater effect size favoring ChEIs in those with PD. Lower baseline cognitive score was associated with increased effect size favoring ChEIs in both AD and PD.

Based on this meta-analysis, ChEIs could be considered in appropriate patients, since ChEIs may reduce hallucinations and delusions in people with AD or PD. Greater effects may be possible if neuropsychiatric symptoms or lower cognitive scores are present at the time of initiation. ChEIs decreased appetite scores in AD, which should be considered in those who are underweight. Whether ChEIs also improve neuropsychiatric symptoms in dementia with Lewy bodies requires further study, since data were insufficient to assess that population in this analysis.

Neurologists at the biggest Alzheimer’s research meeting in the US experienced something this week they hadn’t in years: optimism.

UFMG-V4N2 proved effective in producing antibodies and making them block the passage of cocaine into the brain, which means that the vaccinated animals have a reduced perception of the drug’s effect: a very important advantage in a treatment.

This blockage occurs in the following way: we have a “protective shield” called the blood-brain barrier, which prevents toxic elements, viruses or bacteria from entering the brain, but because the cocaine molecule is very small, it manages to pass through this barrier.

The vaccine stimulates the production of antibodies, which bind to the drug molecules, increasing their weight and size and thus preventing them from getting past the protective shield. The cocaine is retained in the blood, but as it is bound to the antibody, it doesn’t act on the heart or arteries either, which means the risk of overdoses is reduced.

The most recent statistics put the number of regular cocaine or crack cocaine users in the world at 20 million. Of these, one in four will become addicted or develop use disorders.